申请人:Makriyannis Alexandros
公开号:US20090306016A1
公开(公告)日:2009-12-10
Disclosed are compounds of formula R—X—Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CB1i and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide hydrolase (FAAH) action is hot inhibited. Thus, a compound that inhibits the inactivation of endogenous cannabinoid ligands by fatty acid amide hydrolase (FAAH) may increase the levels of endocannabinoids and, thus, enhance the activation of cannabinoid receptors. Thus, the compound may not directly modulate the cannabinoid receptors but has the effect of indirectly stimulating the cannabinoid receptors by increasing the levels of endocannabinoid ligands. It may also enhance the effects and duration of action of other exogenous cannabinergic ligands that are administered in order to elicit a cannabinergic response.
公开了一种R-X-Y式化合物,可用于抑制脂肪酸酰胺水解酶(FAAH)的作用。抑制脂肪酸酰胺水解酶(FAAH)将减缓FAAH水解作用引起的内源性大麻素配体的正常降解和失活,并允许更高水平的内源性大麻素配体保持存在。这些更高水平的内源性大麻素配体提供了对大麻素CB1i和CB2受体的增加刺激,并产生与大麻素受体激活相关的生理效应。它们还将增强其他外源性大麻素配体的效果,并允许它们在较低浓度下产生其效果,与不抑制脂肪酸酰胺水解酶(FAAH)作用的系统相比。因此,一种抑制脂肪酸酰胺水解酶(FAAH)对内源性大麻素配体失活的化合物可能会增加内源性大麻素的水平,从而增强大麻素受体的激活。因此,该化合物可能不直接调节大麻素受体,但通过增加内源性大麻素配体的水平间接刺激大麻素受体。它还可以增强其他外源性大麻素配体的效果和作用持续时间,这些配体被用于引发大麻素反应。